Phergain study
WebA phase two study evaluating folinic acid, fluorouracil, and oxaliplatin (FOLFOX) plus trastuzumab as second- or third-line treatment for HER-2 positive biliary tract carcinoma observed no treatment-related cardiac toxic effects or deaths, while the overall quality of health assessment score (EuroQoL-VAS) did not change significantly throughout … PHERGain was a strategy-based study with a unique design. Previous trials of de-escalation strategies in HER2-positive, early-stage breast cancer have highlighted the importance of establishing innovative clinical designs, together with optimal selection of treatment and study population.
Phergain study
Did you know?
WebA number of clinical trials have been designed to explore a precise treatment for patients receiving neoadjuvant therapy. The aim of CompassHER2-pCR study is to evaluate the de … WebA plain language summary of the PHERGain study Plain Language Summary of Publication future science group www.futuremedicine.com When 18F is combined with FDG it …
WebThe aim of CompassHER2-pCR study is to evaluate the de-escalation of chemotherapy for HER2 positive breast cancer after neoadjuvant chemotherapy and targeted therapy. 4 The PHERGain study will assess the effects of neoadjuvant treatment with dual target therapy (± endocrine therapy according to hormone receptor status) in patients with HER2 … WebÉtude PHERGain : étude de phase 2, randomisée évaluant une stratégie thérapeutique adaptée à la réponse au 18F-FDG PET/CT associant le trastuzumab et le pertuzumab chez des patients ayant un cancer du sein HER2 positif. [essai clos aux inclusions]
WebThe definitive assessment of pathological complete response was done at this primary analysis; follow-up to assess invasive disease-free survival is continuing, hence these … Webthe phergain study CLINICAL TRIAL DETAILS THE STUDY ASSESS THE EARLY METABOLIC EFFECTS OF NEOADJUVANT TREATMENT WITH TRASTUZUMAB AND PERTUZUMAB (± …
Web26. máj 2024 · The PHERGain study was carried out in this medical-scientific context. This phase II clinical trial involved researchers from 45 centres in seven European countries, …
Web3. jún 2024 · PHERGain study . Early results have shown that interim PET seems to be surrogate marker for pCR and the BCS rates are not compromised in the chemo free … point heardWebThe PHERGain study: A.3.2: Name or abbreviated title of the trial where available: PHERGain: A.4.1: Sponsor's protocol code number: MedOPP096-MO39229: A.7: ... The end of study … point heloc reviewsWeb1. máj 2024 · In the recently published PHERGAIN study [36], early metabolic response by FDG-PET showed promise to identify patients who will benefit from anti-HER2 therapy … point henleyWeb2024-10-29. due-trials. Not reported Terminated. 2024-004324-30. A multicenter, randomized, phase II trial evaluating the efficacy of eribulin monotherapy and eribulin plus endocrine therapy in locally- recurrent or metastatic breast cancer patients after progressi... 2024-03-31. due-trials. Reported results. point height fontWeb29. máj 2024 · PHERGAIN In another trial, researchers showed that early evaluation of metabolic response using 18 F-FDG PET/CT could help identify patients who will develop … point hellenthalWeb1. jún 2024 · PHERGain is a response-adapted, strategy-based, multicentre, randomised, open-label, non-comparative, phase 2 study done in 45 hospitals in seven European countries (Spain, France, Belgium, Germany, the UK, Italy, and Portugal; appendix pp 18–19 ). point herndonWebIt is actually the essential chemotherapy in neoadjuvant therapy, the PHERGain study shows that there are patients who can achieve a complete pathological response only with the … point heron wa